Published in Cancer Weekly, September 27th, 2005
Tamoxifen, which is actually the gold standard adjuvant treatment in estrogen receptor-positive early breast cancer, is associated with an increased risk of endometrial cancer and other life-threatening events," according to recent research from Italy. "Moreover, many women relapse during or after tamoxifen therapy because of the development of resistance."
"Therefore new approaches are required," stated F. Boccardo and colleagues. They "conducted a prospective randomized trial to test the efficacy of switching postmenopausal patients who were already receiving...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Cancer Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.